PD-1/PD-L1 inhibitors remain the dominant class in the bladder cancer market in terms of patient share, and label expansion into earlier disease stages such as non-muscle invasive bladder cancer and muscle invasive bladder cancer will further grow the overall bladder cancer market. 

Although plagued by doubts surrounding PD-1/PD-L1 inhibitors’ performance in the first-line metastatic setting, data for the combination of Keytruda + Padcev showed a strong survival benefit regardless of cisplatin eligibility or PD-L1 status, leading to an approval in the US. 

This Datamonitor Healthcare report contains a Disease Analysis module.